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Abstract: Based on current literature authors reviewed information on bile metabolism, i.e. produc-
tion and chemical compounds, synthesis of bole acids, their hepato-intestinal circulation with respect 
to etiology of cholelithiasis — its epidemiology and clinical aspects. 
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INTRODUCTION
Bile is a result of osmotic filtration and is permanently released by hepatocytes 
into biliary canaliculi, about 500–600 ml/24 hrs. This so called canalicular frac-
tion is about 80% of daily production. The remaining volume of the bile arises 
from epithelium lining intrahepatic biliary tracts (cholangiocytes). Bile of the liver 
is relatively isotonic in comparison to the blood serum. Entire concentration of 
substances dissolved in the hepatic bile is 30–40 g/l.
Bile is a complex liquid containing 95% of water and dissolved substances i.e. 
salts of biliary acids (80%), phospholipids — mainly lecithin (16%), free, non-es-
terified cholesterol (4%), also others: conjugated bilirubin, proteins, electrolytes, 
mucus, medications and their metabolites [1]. 
It is worth to mention that lithogenity may increase percentage of non-esteri-
fied cholesterol till 8–10% of the total amount of dissolved substances.
The next compound of the bile are biliary pigments: bilirubin conjugated with 
glucuronic acid (in the form of mono- and diglucuronates) and biliverdin. Biliru-
bin is product of hemoglobin degradation, released from damaged erythrocytes. It 
arises in reticulo-endothelial system of the liver, bony marrow and spleen. Such 
bilirubin is referred to as free (non-conjugated), it is poorly water soluble; its sol-
ubility increases that to conjugation with blood serum albumin. In the liver free 




Lipids Sterols  cholesterol (95% out of all sterols of the bile)
    remaining sterols
 Phospholipids mainly phosphatydylocholin (lecithin)
 Bile acids  primary: cholic acid, chenodeoxycholic acid
    secondary: deoxycholic acid, lithocholic acid
    tertiary: ursodeoxycholic acid, suphofofitocholans
Proteins Albumins
 Immunoglobulins IgG, IgM
 Apolipoproteins  AI, AII, B, CI, CII
    Transferin
    a2-macroglobulin
 other proteins EGF, insulin, haptoglobin, CCK, amylase, lisosomal 
    hydrolase
Ions    sodium, potassium, calcium, magnesium, phospho- 
    rus, zinc, iron, manganium, molibden, strontium, 
    cuprum 
Bile pigments   bilirubin, biliverdin
SYNTHESIS OF BILE ACIDS
Bile acids arise in the liver and are end-products of cholesterol metabolism. Syn-
thesis of bile acids is the main physiologic mechanism thank to which organism 
is able to remove excess of cholesterol. 
Bile acids can be divided into primary, i.e. cholic and chenodeoxycholic ac-
ids, and secondary. Primary bile acids are synthetized in the liver during a mul-
tienzymatic process in which non-water soluble, electrically neutral particle of 
cholesterol is transformed into ionized water-soluble particle of bile acid. Initial 
stage of bile acid synthesis is addiction of hydroxide group to cholesterol in 7a 
position. This reaction is dependent on 7a-hydroxylase. Before the bile is se-
creted both acids are conjugated in hepatocytes partially with glycine (70%) and 
partially with taurine (30%, what increases their polarity and water solubility. 
Because mentioned acids exist in a bile as salts of different cations, i.e. sodium, 
potassium, they are also referred as bile acids.
Next they are actively secreted on the biliary pole of the hepatocyte into bili-
ary canaliculi, and then become bile components, to travel together to the intes-
tine. In a distal fragment of ileum and in the large colon aerobic bacteria using 
enzymatic de-conjugation (removal of glycine and taurine residues) and dehy-
droxylation (removal of hydroxide group from 7a position) transform cholic acid 
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into deoxycholic and chenodeoxycholic into lithocholic respectively. Such complex 
substances are referred to as secondary bile acids. Part of the undergoes further 
modification under the influence of intestinal flora or after resorption in the liver 
to so called tertiary bile acids, which are represented i.e. by ursodeoxycholic acid 
(7a-epimer of chenodeoxycholic acid), or sulphofitocholan which is derivative of 
lithocholic acid. Lithocholic acid is poorly water soluble and mainly removed with 
feces.
Thank to bile acids some water-insoluble substances i.e. cholesterol, metabo-
lites of hormones and medications can be transported in the water environment 
of the bile. In the small intestine bile acids facilitate emulgation of fats, i.e. tria-
cyloglycerols, what results in a better exposure to pancreatic lipases. Fatty acids 
facilitate intestinal absorption of vitamins fat-soluble (A, D, E, K).
Regulation of synthesis of bile acids is determined by many factors, i.e. func-
tional condition of hepatocytes, cholesterol availability (precursor particle), and 
also by amount of salts of biliary acids migrating back to the liver by the help 
of hepato-intestinal circulation.
HEPATOINTESTINAL CIRCULATION OF BILE ACIDS
In the lumen of small intestine bile acids enable emulgation of lipids and ab-
sorption of fat soluble vitamins. Conjugation of bile acids with glycine or taurine 
in the liver changes their physicochemical features, causing fact that they are 
not absorbed in the duodenum nor in the jejunum. Thus their concentration re-
mains relatively high in upper small intestine until the moment when digestion 
and absorption of fats is completely finished. 
Most (95%) of bile acids, which get with bile to intestines is actively absorbed 
in the peripheral ileum and after binding with proteins returns back to the liver 
through portal circulation, to be actively released to the bile. So, newly synthe-
tized bile acids of the liver account for about 5% of the total amount of their 
number and compensate loss of these acids which were not absorbed in the in-
testine but removed with the feces.
The cycle of hepato-intestinal circulation of bile acids repeats 6–10 times per 
day. Total amount of bile salts in the body reaches 2–4 g, and the amount nec-
essary to a human during 24 hrs. to digest the fats is around 15–20 g. This is 
why their permanent circulation is necessary. Intestinal absorption of bile acids 
may be disabled in the following situations: state after resection of small in-
testine, Leśniowski-Crohn’s disease, after application of cholestyramin (ion-ex-
change resin which binds salt of bile acids). In such situation interruption of 
the hepato-i testinal circulation of bile acids occur and increase of their removal 




Diseases of biliary tracts existed in humans for many years. The proves are gall-
stones found in mummified cadaver of young priestess living in XI century BC, 
and the first description of the jaundice caused by cholelithiasis, made by Soranos 
from Efez in IInd century [2, 3]. A very precise description of a case of cholelithi-
asis was given by pathologist Antonio Benivenius in 1507 [4]. Through ages the 
diseases of biliary tracts and their complication were one of the most common 
causative factors of death of patients, because although properly diagnosed still 
in XVIIIth century, they were inappropriately treated. Efficacious tactic in treat-
ment of the diseases of biliary tracts is based on surgical procedures, but pa-
tients and medical doctors had to wait until second half of XIXth century, when 
Lawson Tait in 1879 in his hospital in Spark Hill in Birmingham popularized 
cholecystotomy, it means surgical removal of the gallstones without removing the 
gallbladder [5]. Critical date in gallbladder surgery was 1882, when on July 15th 
Karl von Langenbuch made in Berlin first in the world cholecystectomy, it means 
surgical removal of the gallbladder together with the gallstones [6]. Through the 
next 100 years this operation was a standard of surgical procedure in case of 
cholelithiasis. In 1987 Philippe Mouret, a surgeon from Lyon — carried out for 
the first time laparoscopic cholecystectomy [7, 8]. It is worth to mention that first 
laparoscopic cholecyctectomy in Poland was carried out by prof. Marek Krawczyk 
in 1991.
Undertaken attempts of conservative treatment changed throughout the years, 
but as widely known there is no reliable, secure and effective method for inop-
erative treatment of cholelithiasis.
EPIDEMIOLOGY
Cholelithiasis is a disease which is relatively common in well-developed coun-
tries. Epidemiologic studies in USA show that cholelithiasis involves 6,3 millions 
of males and 14,2 millions of females at the age between 20 and 74 [9]. One 
of the widest European epidemiological studies of the cholelithiasis was an Ital-
ian study of MICOL (Multicentric Italian Study on Cholelithiasis). The research 
covered almost 30 thousands of individuals at the age between 30 and 69. In 
a screening carried out on the studied group they found cholelithiasis in 18,8% of 
the females and 9,5% of the males [10]. Obtained epidemiologic data from Med-
iterranean region do not differ significantly from the rest of the Europe, where 
frequency of the disease is estimated on 10–15% of the males and 25% of the 
females [11]. The highest indexes were observed in Indians Pima in Northern 
America, in citizens of US of Mexican origin, the lowest in people of Bantu and 
Masai in Africa, where this disease practically does not occur [12, 13].
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Despite most of people suffering from cholelithasis is clinically inarticulate, 
symptomatic cholelithiasis is considered to be the most frequent and most ex-
pensive disease in the United States [14].
ETIOLOGY OF THE CHOLELITHIASIS
From a definition — cholelithiasis is a condition where concretions are placed in 
the gallbladder (cholecystolithiasis) and/or in the biliary tracts (choledocholithi-
asis). Creation of the concretions is genetically and environmentally determined. 
The frequency of the cholelithiasis increases with ageing. Morbidity in the females 
is 2–3 times bigger than in the males. The next, important risk factor is obesity. 
In many screening tests it was shown the linear dependence between body mass 
index (BMI) and the frequency of the disease [15–18]. The stages which predis-
pose to bile retention and creation of the concretions in the gallbladder are: di-
abetes, injuries of the spinal cord with autonomic nervous system dysfunction, 
and complete parenteral nutrition [19].
CLINICAL ASPECTS
Cholecystolithiasis is usually asymptomatic (80%), and in 1–4% yearly becomes 
symptomatic [20, 21]. In about 12% of cases cholecystolithiasis coincidences with 
the choledocholithiasis [22].
The most typical sign of gallstone disease is a biliary colic, which may exist 
in 10–30% of diseased patients [22]. Preferably it is followed by acquisition of 
a fatty meal and is associated with sharp agonizing pain in right hypochondriac 
region, and central epigastrium, radiating to right scapular region. Colic is com-
monly accompanied by emesis, always by nausea. In a typical, non-complicated 
colic there is no increase of the body temperature. Pain in the colic is a typical 
visceral pain and is caused by contractions of the gallbladder and the biliary 
tracts freed by irritation resulted from passage of the gallstone. It is associat-
ed with increase of the pressures in the gallbladder and biliary tracts [23]. Pain 
fades within few hours.
The main complication of the gallstone disease are: acute cholecystitis, inflam-
mation of the biliary tracts and acute pancreatitis, hepatic abscesses, mechanical 
jaundice and liver cirrhosis, first of all cancer of the gallbladder.
Cholecystitis is mostly forwarded by cholelithiasis. It may be recognized when 
after hepatic colic attack symptoms of pain and rebound tenderness last more 
than 6 hrs. within the right hypochondriac region (positive signs of Chełmoński 
and Murphy), with muscle defense, fever and leukocytosis. The most frequent is 
aseptic inflammation, which is a reaction of the gallbladder wall to biochemical 
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changes of the bile, irritation of the gallstones, increase of the pressure and ex-
pansion of the gallbladder wall when the natural flow of the bile is closed. 
A particular form of cholecystitis is a hygroma of the gallbladder, which forms 
when with obstructed cystic duct there is no sign of infection of its content nor 
necrosis of the wall of gallbladder. In such case the content of the gallbladder 
is so called “white bile”, which develops in response to increased secretion by 
mucosa muco-serous liquid accompanied by reabsorption of the bilirubin and 
bile salts. The gallbladder significantly increases because of fluid accumulation. 
For the most part is slightly painful and easy palpable during physical examina-
tion. When content of the gallbladder is infected and empyema may develop. The 
gallbladder is then painful and guarded by muscular defense. Fever is usually 
hectic. The signs of local peritonitis in the right hypochondriac region prove ne-
crotic cholecystitis or subsequent perforation of the gallbladder. Perforation may 
occur into peritoneal cavity (greater sac) or space limited by neighboring organs. 
In this last case a local empyema may develop with local peritonitis limited to 
right upper quadrant of the abdomen.
In case of formation of the fistula between gallbladder and the lumen of neigh-
boring organ, most frequently the duodenum — the content of the gallbladder 
together with the gallstones empties into the lumen of gastrointestinal tract. It 
leads to regression of the signs of cholecystitis and general recovery of the pa-
tient. Although later mechanical obstruction may develop, and its causative fac-
tor is gallstone causing obstruction of ileum. 
A consequence of chronic prolonged presence of gallstones within the gallblad-
der is its chronic inflammation. Because of the chronic inflammation the wall 
of the gallbladder becomes thicker, fibrous and hardens, while the gallbladder 
becomes smaller (cirrhotic). 
The cholelithiasis and chronic inflammation are per se associated with a risk 
of cancer of the gallbladder [24, 25]. Nowadays it widely postulated that asymp-
tomatic cholelithiasis is not absolute indication for operative treatment.
The treatment of choice of the symptomatic, non-complicated cholelithiasis is 
a surgical excision of the gallbladder together with concretions.
PATOPHYSIOLOGY OF CHOLESTEROL GALLSTONE FORMATION
Gallstones can be subdivided following their chemical composition: this is why 
we can distinguish cholesterol gallstones (over 50% of their mass is consisted of 
cholesterol), mixed (20–50% content of cholesterol) and pigment (they contain less 
than 20% of cholesterol and the main compound is calcium bilirubinate) [26]. 
Following the epidemiologic studies in Europe and America cholesterol and mixed 
concretions dominate, pigment concretions are more common in Asian countries, 
in Europe they can be found extremely rare [27–29].
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The source of cholesterol for the organism is its intake with food and hepatic 
synthesis de novo from acetyl coenzyme-A. Cholesterol is eliminated from the body 
through its secretion to the bile as free element or conjugated with salts of bile acids. 
Cholesterol is practically water-non-soluble. Its solubility in bile is resulted 
from interactions with other particles [30]. Cholesterol carriers are micelles and 
lecithin vesicles.
The lecithin vesicles are spherical, unilamellar, bilayerous structures — 40– 
100 nm. Apart from the cholesterol and phospholipids they contain small amounts 
of salts of bile acids. More than 95% of phospholipids are diacyl phosphatydyl-
cholins (lecithins). Their polar cholic residua are directed to water phase, and the 
chains of lipid acids till internal phospholipid bilayer, where they create hydro-
phobic milieu for cholesterol particles. Lecithin vesicles are thermodynamically 
metastabile and undergo conversion into other lipid aggregates during balance 
achieving by the bile present in the paths and gallbladder.
The particles of bile acids conjugated with tauryn or glycine are amphipathic, 
what means that they possess both hydrophilic and hydrophobic (lipophile) do-
mains. In water solution, salts of bile acids exist as monomers. With achieving 
a certain concentration, so called critical micellar concentration (CMC) the par-
ticles (monomers) of the bile acids automatically create aggregates in the bile, 
named micellae, in which the hydrophilic poles are directed to the outside — into 
water environment, while hydrophobic “tails” composed of fatty acids to the in-
terior. This is how the contact of hydrophobic domains with water is minimized, 
and the interior of the micelle forms an “enclave”, where water-insoluble sub-
stances, i.e. cholesterol and fat-soluble vitamins are maintained in a fluid state. 
Process of aggregation of bile acids into micellae is gradual and begins at the 
value of MCM about 2 mmol/L [1].
Concluding, cholesterol is bile-soluble, because it is an element of such micellae.
The bile, as mentioned above, is consisted of simple micellae (composed of 
bile acids only), discoid in shape with diameter about 3 nm and mixed micellae 
(composed of bile acids and lecithin) — 4–8 nm in diameter. These last dissolve 
averagely 3 times more cholesterol that simple micellae. Only the micellar solu-
tions of cholesterol can be described as thermodynamically stabile. 
Lipids, i.e. cholesterol, phosphatydylcholine (lecithine) and bile salts are se-
creted to bile using ATP-dependent proteins carriers (ABC transporters) [31].
After secretion into the bile, cholesterol and phospholipids form lecithin ves-
icles, and the salts of bile acids aggregate into simple micellae. In normal con-
dition, when the amount of bile salts is appropriate all listed above lipid aggre-
gates are transformed during their transition with bile to the vesicle into mixed 
micellae [31]. This is how cholesterol remains stable in a solution during trans-
port through the biliary system (unsaturated bile).
If the bile contains more cholesterol, that it can be dissolved in the form of 
mixed micellae, it means that it is supersaturated with cholesterol. Then nucleation 
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phenomenon occurs, which is associated with aggregation and fusion unilamel-
lar vesicles supersaturated with cholesterol into bigger multilamellar structures 
(around 500 nm in diameter), known as liposomes or liquid crystals. These vesi-
cles can be seen in polarization light microscope as bifragile droplets resembling 
Maltese cross. The process of nucleation is followed by coming into being the 
crystals of cholesterol monohydrate, so crystallization. More, the gallbladder se-
cretes mucous glycoproteins, which form the matrix for precipitation of the ag-
gregates of cholesterol crystals into gallstones. 
In 60-ties Admirand and Small (1968), and earlier Isaksson (1951) suggest-
ed that cholesterol gallstones resulted from excessive secretion of cholesterol 
through the liver into the bile, what resulted from liver disturbances (hepatocytes) 
or problems in other points of hepato-intestinal circulation (i.e. in the intestine) 
[30, 32]. 
It is postulated nowadays that formation of cholesterol gallstones is caused by 
simultaneous action of many factors, which show different level of importance, 
leading together to formation of nuclei (nucleation), cholesterol monohydrate crys-
tallization and as a consequence creation of gallstones [1, 33, 34]. These basic 
pathophysiologic factors can be presented as the following events:
• Supersaturation (oversaturation) of bile with cholesterol due to its hepatic hy-
persecretion and/or decrease of secretion of salts of bile acids.
• Decrease of motor activity of the gallbladder leading to bile retention (biliary 
stasis) and acceleration of cholesterol crystallization within the bile
• Increase of mucous secretion in the gallbladder [34].
Admirand and Small defined the lithogenous bile as the bile which contains 
excess of the cholesterol, it means more that it can be normally found within 
simple and mixed micellae or lecithin vesicles. They estimated values of choles-
terol solubility using diagram of phase balance [30].
Based on these conceptions, in patients with gallstones, a lithogenous bile 
was generally found (apart from the non-cholesterol lithiasis), while in healthy 
individuals bile was unchanged or non-saturated. It is however partially true, be-
cause in healthy individuals during fasting state, supersaturated bile can exist 
(Northfield et al. 1975) [35].
Supersaturation of bile with cholesterol (oversaturation) binds with the pres-
ence of cholesterol excess in comparison to phospholipids and bile acids concen-
tration. This is why based on the current literature one can describe three main 
anomalies of secretion (Holzbach and Kibe 1985) [36]:
Type 1 — shortage of lipid carriers of cholesterol in bile, caused by absolute 
decrease of bile acids and/or phospholipids secretion;
Type 2 — increased secretion of cholesterol (hepatic hypersecretion), so ab-
solute increase of cholesterol secretion into the bile, as it is observed in obesity
Type 3 — connection of phospholipids/ bile salts shortage with excessive se-
cretion of cholesterol
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The excess of cholesterol secreted into the bile by hepatocytes, causes its su-
persaturation, despite normal secretion and level of salts of bile acids. Cholesterol 
hypersecretion is found in obesity. It results from increased activity of enzyme: 
hepatic reductase 3-hydroxy-3-methyl-glutarate-coenzyme A (HMG-CoA-reductase), 
with a consequence of increased production and secretion of cholesterol into the 
bile [37, 38].
The normal cholesterol secretion in the presence of decreased amount of bile 
acids, due to shortage of their hepato-intestinal return or secretion volume, leads 
to hypersaturation of bile with cholesterol.
Despite the fact that cholesterol gallstones arise in the presence of lithogenous 
bile, supersaturation itself is not sufficient factor for lithogenesis. Most of individ-
uals with supersaturated bile do not develop lithiasis, because the time necessary 
for nucleation, cholesterol crystallization and growth of the gallstone is longer 
than time of bile retention in the gallbladder. Bile retention is the next gallstone 
disease predisposing factor. Risk of cholelithiasis increases in all conditions as-
sociated with shortage of gallbladder emptying. These conditions are: pregnancy 
[39], complete parenteral nutrition [40]. During the pregnancy the volume of the 
gallbladder while fasting state and residual capacity increase with level of serum 
progesterone concentration, which through inhibition of contractility of smooth 
muscle exacerbates gallbladder emptying. In patients with parenteral nutrition 
one can observe decrease of cholecystokinin release [41]. Similar phenomenon 
exists in interdigestive state, when lack of meal stimulation slows down the mo-
tor activity of the gallbladder. Disturbances with gallbladder emptying are rela-
tively common in suffering from cholelithiasis. Functional ultrasonography tests 
showed that patients with gallstone disease have increased residual and fasting 
state capacity of the gallbladder in comparison to the control. Complete emptying 
did not differ in both groups studied, however partial emptying during interdi-
gestive state was short [42].
The dependence between the motor activity of the gallbladder and the duo-
denum during interdigestive state is very important. It was observed that gall-
bladder empties partially also in this period (about 20–30% of output volume in 
comparison to 70–80% decrease of the volume after meal) and then refills. It oc-
curs within 1–2hrs intervals and is associated with intestinal cycle of Migrating 
Myoelectric or Motor Complex (MMC) accompanied by simultaneous increase of 
motilin in blood serum [43, 44]. MMC and its relationship with gallbladder motor 
activity was briefly described in [45]. During period of hunger the bile is slowly 
concentrated in the gallbladder, what is counteracted by temporary motor activ-
ity of the gallbladder coordinated with phase III of MMC [46]. Bile condensation 
results in consequences as: increased solution of cholesterol (and phospholipids) 
in micellae. Because phospholipids ae more soluble in micellae than cholester-
ol,they use to migrate from vesicles into micellae. The remaining vesicles rich in 
cholesterol reveal a tendency to create nuclei — nucleation of cholesterol crystals. 
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Following this thesis, decreased frequency of phase III of MMC and lack of gall-
bladder contractility during interdigestive state seen in patients with cholelithiasis 
promotes bile condensation, crystallization, and gallstone formation [47]. 
Suppression of CCK release by somatostatin or its analogues administered to 
the diseased because of acromegaly, significantly increases the risk of cholester-
ol cholelithiasis development through reduction of gallbladder contractility [48]. 
Similar effect of decrease of gallbladder contractility was achieved during studies 
on mice with deletion of CCK-1 receptor coding gene [49].
Bile contains few proteins, which promote crystallization and gallstone devel-
opment, i.e. mucus glycoproteins — mucine. Excess in mucine secretion was ob-
served in animal models of cholethogenesis (Carey and Cahalane 1988) [34], Lee 
1981 [50, 51]. Following some reports saturation of bile with cholesterol cause 
probably through the prostaglandin mechanism , increased secretion of mucus 
by epithelial cells of the gallbladder wall [51, 52]. 
As a result of increased synthesis and mucine secretion above critical lev-
el, epithelium of the gallbladder covers with mucine gel. This gel sticks lecithin 
vesicles overloaded with cholesterol, what causes that this gel becomes a factor 
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